TUESDAY, Aug. 19, 2025 (HealthDay News) -- Infants up to 6 weeks of age with genetically diagnosed spinal muscular atrophy (SMA) who are treated with risdiplam
Risdiplam Beneficial for Infants With Genetically Diagnosed Spinal Muscular Atrophy
HealthDay1 hrs ago
123
Associated Press Top News
America News
The US Sun Health
Sun Sentinel
Futurism
KUOW Public Radio
WKOW 27
Verywell Health
Raw Story
Foreign Policy